Te rlip resina m ás a lbúmina como tratamien to de l s índ rome hepa torrena l tipo 1 - C. Lagos C. et al.
Medicina Basada en la evidencia en Gastroenterología
Referencias
1.- Boyer T, Sanyal A, Wong F,
Frederick RT, Lake JR, O’Leary JG,
et al. Terlipressin plus albumin is
more effective than albumin alone in
improving renal function in patients
with cirrhosis and hepatorenal syndrome
type 1. Gastroenterology 2016; 150:
1579-89.
2.- Murray CJ, Atkinson C, Bhalla K,
Birbeck G, Burstein R, Chou D, et al.
The state of US health, 1990-2010:
burden of diseases, injuries, and risk
factors. JAMA 2013; 310: 591-608.
3.- Valdivia G, Margozzini P, Garrido M,
Villarroel L, de la Cruz R, Olea R, et al.
Encuesta Nacional de Salud 2010; 1:
556-74.
4.- Angeli P, Ginès P, Wong F, Bernardi M,
Boyer TD, Gerbes A, et al. Diagnosis
and management of acute kidney injury
in patients with cirrhosis: Revised
consensus recommendations of the
International Club of Ascites. J Hepatol
2015; 62: 968-74.
5.- Salerno F, Gerbes A, Ginès P, Wong F,
Arroyo V. Diagnosis, prevention and
treatment of hepatorenal syndrome in
cirrhosis. Gut 2007; 56: 1310-8.
6.- Arroyo V, Ginès P, Gerbes AL,
Dudley FJ, Gentilini P, Laffi G, et al.
Definition and diagnostic criteria of
206
refractory ascites and hepatorenal
syndrome in cirrhosis. International
Ascites Club. Hepatology 1996; 23:
164-76.
7.- Esrailian E, Pantangco ER, Kyulo NL,
Hu KQ, Runyon BA. Octreotide/
Midodrine therapy significantly improves
renal function and 30-day survival
in patients with type 1 hepatorenal
syndrome. Dig Dis Sci 2007; 52: 742-8.
8.- Narahara Y, Kanazawa H, Taki Y,
Kimura Y, Atsukawa M, Katakura T, et
al. Effects of terlipressin on systemic,
hepatic and renal hemodynamics in
patients with cirrhosis. J Gastroenterol
Hepatol 2009; 24: 1791-7.
9.- Ginès P, Guevara M, Arroyo V, Rodés J.
Hepatorenal syndrome. Lancet 2003;
362: 1819-27.
10.- Lenz K, Hörtnagl H, Druml W,
Reither H, Schmid R, Schneeweiss B,
et al. Ornipressin in the treatment of
functional renal failure in decompensated
liver cirrhosis. Effects on renal
hemodynamics and atrial natriuretic
factor. Gastroenterology 1991; 101:
1060-7.
11.- Alessandria C, Ozdogan O, Guevara M,
Restuccia T, Jiménez W, Arroyo V, et al.
MELD score and clinical type predict
prognosis in hepatorenal syndrome:
relevance to liver transplantation.
Hepatology 2005; 41: 1282-9.
12.- Gluud LL, Christensen K, Christensen E,
Krag A. Terlipressin for hepatorenal
syndrome. Cochrane Database Syst Rev
2012; 9: CD005162.
13.- Sanyal AJ, Boyer T, García-Tsao G,
Regenstein F, Rossaro L, Appenrodt B,
et al. A randomized, prospective,
double-blind, placebo-controlled trial
of terlipressin for type 1 hepatorenal
syndrome. Gastroenterology 2008; 134:
1360-8.
14.- Sagi SV, Mittal S, Kasturi KS,
Sood GK. Terlipressin therapy for
reversal of type 1 hepatorenal syndrome:
a meta-analysis of randomized controlled
trials. J Gastroenterol Hepatol 2010; 25:
880-5.
15.- Martin-Llahí M, Pepin MN, Guevara M,
Díaz F, Torre A, Monescillo A, et al.
Terlipressin and albumin vs albumin in
patients with cirrhosis and hepatorenal
syndrome: a randomized study.
Gastroenterology 2008; 134: 1352-9.
16.- Solanki P, Chawla A, Garg R, Gupta R,
Jain M, Sarin SK. Beneficial effects of
terlipressin in hepatorenal syndrome:
a prospective, randomized placebo
controlled clinical trial. J Gastroenterol
Hepatol 2003; 18: 152-6.
17.- Fabrizi F, Dixit V, Messa P, Martin P.
Terlipressin for hepatorenal syndrome: A
meta-analysis of randomized trials. Int J
Artif Organs 2009; 32: 133-40.
Gastroenterol. latinoam 2017; Vol 28, Nº 3: 202-206